Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bluejay Diagnostics (BJDX) Free Cash Flow (2022 - 2023)

Bluejay Diagnostics (BJDX) has disclosed Free Cash Flow for 2 consecutive years, with -$2.9 million as the latest value for Q4 2023.

  • Quarterly Free Cash Flow fell 41.55% to -$2.9 million in Q4 2023 from the year-ago period, while the trailing twelve-month figure was -$9.0 million through Dec 2023, down 15.87% year-over-year, with the annual reading at -$6.2 million for FY2025, 23.38% up from the prior year.
  • Free Cash Flow hit -$2.9 million in Q4 2023 for Bluejay Diagnostics, down from -$1.2 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of -$1.2 million in Q3 2023 to a low of -$3.3 million in Q1 2023.